FRONT PHARMACOL:非诺贝特可以将新冠感染减少超70%

2021-08-19 K.K MedSci原创

非诺贝特可以减少新冠病毒引起的感染,其治疗效果高达70%

非诺贝特(fenofibrate)已经被世界上大多数国家批准使用,包括FDA和英国国家健康和护理卓越研究所(NICE),它是一种口服药物,目前用于治疗血液中胆固醇和脂质水平高的情况。一项由国际合作研究人实验室研究显示,非诺贝特可以减少新冠病毒引起的感染,其治疗效果高达70%,这项研究发表在近日的《药理学前沿》上。

 

Scott P. Davie et al.The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models.Frontiers in Pharmacology.DOI: 10.3389/fphar.2021.660490

英国伯明翰大学等领导的研究小组证明:非诺贝特及其活性形式(非诺贝特酸)可以在实验室中显着减少新冠感染人体细胞,且使用标准的临床剂量即可以实现。

该团队现在呼吁在住院的COVID-19患者中测试该药物。在这项研究中,为了应对全球COVID-19大流行,该团队测试了一组已经获得许可的药物非诺贝特,以确定破坏ACE2和Spike相互作用的候选药物。他们在实验室中使用le 2020年分离出的新冠病毒的原始毒株测试了该药物在减少感染人体细胞方面的功效。他们发现非诺贝特能减少高达70%的感染。其他未发表的数据也表明,非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效,并且正在研究其对δ变体的功效。

英国伯明翰大学的Farhat Khanim博士解释说:"更具传染性的新冠变体导致世界上一些国家的感染率和死亡人数迅速扩大,特别是英国、美国和欧洲。虽然疫苗项目有望在长期内降低感染率和病毒传播,但仍然迫切需要扩大我们的药物库,以治疗新冠病毒的阳性患者。"

英国基尔大学的Alan Richardson博士补充道:"虽然一些国家的疫苗接种计划正在快速推进,但疫苗的吸收率是在不断变化,对于大多数中低收入国家来说,相当大比例的人口在2022年前不太可能接种疫苗。虽然疫苗接种已被证明可以降低感染率和疾病的严重程度,但我们还不能确定反应的强度和持续时间,目前,仍然迫切需要治疗方法来管理出现症状或住院治疗的新冠患者。”

意大利米兰圣拉斐尔科学研究所的Elisa Vicenzi博士说,"我们的数据表明,非诺贝特可能可以降低新冠症状的严重程度,也有可能降低病毒传播。鉴于非诺贝特是一种口服药物,非常便宜,且在全世界都可以买到,再加上其广泛的临床使用历史和良好的药物安全性,这项数据尤其有意义,特别是在中低收入国家和那些不建议或不适合使用疫苗的人,如儿童、患有高免疫性疾病的人和使用免疫抑制剂的人。"

伯明翰大学的Scott Davies博士总结说:"我们现在迫切需要进一步的临床研究来确定非诺贝特是否是治疗新冠感染的潜在治疗药物。"

原文出处:

Scott P. Davie et al.The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models.Frontiers in Pharmacology, DOI: 10.3389/fphar.2021.660490

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
    2021-08-28 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
    2021-11-09 jj000001
  6. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
    2021-09-19 涂涂0518

    学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
    2021-08-20 564604711

    非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1788440, encodeId=e9bb1e88440c6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Sep 10 12:18:09 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908653, encodeId=ce8e19086532b, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 27 03:18:09 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996423, encodeId=a7b31996423d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Aug 28 15:18:09 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705795, encodeId=371b1e0579514, content=<a href='/topic/show?id=e64f99689dd' target=_blank style='color:#2F92EE;'>#非诺贝特#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99689, encryptionId=e64f99689dd, topicName=非诺贝特)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea031086851, createdName=jktdtl, createdTime=Sat Oct 30 00:18:09 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787737, encodeId=0e101e8773736, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 09 21:18:09 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052955, encodeId=0e4d105295598, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Sun Sep 19 07:40:49 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009670, encodeId=93da10096e02f, content=非诺贝特非诺贝特对SARS-CoV-2的较新的变体包括α和β变体同样有效。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210820/8ce0485679384f63908ad2b911a43330/fe7912bfbfaa4024902e71688bf84b2a.jpg, createdBy=bd552909298, createdName=564604711, createdTime=Fri Aug 20 10:44:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029882, encodeId=dd4b102988216, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Aug 19 20:18:09 CST 2021, time=2021-08-19, status=1, ipAttribution=)]
    2021-08-19 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

幽门螺杆菌有疫苗吗?快了!

2021年4月10日,山西康宝生物制品股份有限公司官方微信宣布,该公司申报的一类新药”口服幽门螺杆菌基因工程活菌载体苗“正式进入临床试验。

张文宏凌晨发长文解读南京疫情,关键在于后续1-2周的监测

近期南京疫情跨省传播,成为大家最关心的话题之一。

JCC:免疫力低下的炎症性肠病患者接种新冠疫苗后的T细胞反应与常人一致

自此2019年年末的一场突入起来的新冠疫情爆发以来,急性呼吸系统综合症冠状病毒 2 (SARSCoV-2) 的全世界大流行给 IBD 患者的治疗带来了非常重大的挑战。

JAMA:肾移植受者应接种三剂mRNA-1273 SARS-CoV-2疫苗

器官移植受者可考虑使用第三剂疫苗。

雾化吸入免疫获突破!全球雾化给药新冠疫苗发表

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 v